Inspire Medical Systems, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023 and Full Year 2024
January 08, 2024 at 08:00 am EST
Share
Inspire Medical Systems, Inc. Provided Revenue Guidance for the fourth quarter and full year of 2023 and full year 2024. For the quarter, Revenue is anticipated to be in the range of $192.3 million to $192.5 million, an approximately 40% increase over the same quarter of 2022.
For the full year of 2023, Revenue is anticipated to be in the range of $624.6 million to $624.8 million, an approximately 53% increase over full year 2022.
For the full year 2024, Revenue is anticipated to be in the range of $775 million to $785 million, a 24% to 26% increase over full year 2023.
Inspire Medical Systems, Inc. is a medical technology company. The Company is focused on the development and commercialization of advanced, minimally invasive solutions for patients with obstructive sleep apnea (OSA). Its proprietary Inspire system is the FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. The Company has developed a novel, closed-loop solution that continuously monitors a patientâs breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The Company sell its Inspire system to hospitals and ambulatory surgery centers (ASCs) in the United States (U.S.) and in select countries in Europe and Japan through a direct sales organization and sells its Inspire system in Singapore and Hong Kong through distributors. Its direct sales force engages in sales efforts and promotional activities focused on ENT physicians and sleep centers.